R & D

Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

 This material is intended to notify the press release issued on January 22 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click https://www.bms.com/media/press-releases.html for the original press release.